Remove tag
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty side effects. If the drug is approved you can bet that it’s going to carry a huge price tag. Will they follow the science or will they put a price tag on hope?

article thumbnail

Beyond the Price Tag: How Hospital Admins, Doctors, and Patients Define Medical Value

Contrarian Sales Techniques

Doctors: Clinical Outcomes and Patient Care On the other side of the spectrum, doctors view value through a clinical lens. Does a new drug have fewer side effects? For them, it's all about patient outcomes. Does a particular treatment lead to faster recovery? These are the questions they grapple with daily.

Doctors 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

But along with strong efficacy come some considerable risks and costs: cytokine release syndrome (CRS), where a patient’s immune system becomes dangerously over-stimulated, and neurotoxicity are potential side effects that need to be managed. Side effects and cost implications.

article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 million in the US and just under €2 million in Europe, which the company says is justified by its dramatic benefits when given as a one-shot therapy to patients with SMA.

article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

What’s more, 40 percent of those subjects suffered side effects, including severe brain swelling. Not to mention the $56,000 annual price tag. The finding was far lower than the one to two points generally considered to be statistically significant improvement. That might be tolerable if the drug actually worked.

FDA 218
article thumbnail

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

Adverse events such as bruising, headaches, and blood in urine occurred at roughly the same frequency in both groups of patients in ADVANCE IV, and while serious side effects were seen in 8% of the Vyvgart group, that was lower than the 16% reported with placebo.

article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

Additionally, when patients are prescribed medication, they are often unaware of the mechanism of action, potential side effects, interactions, and contraindications. There are many reasons for patient non-adherence, including high medication costs, fear of potential side-effects, and forgetfulness, amongst others.